… (b) Changes in the proportion of metastatic lung cancer patients surviving five years as a
function of age and year of diagnosis. The symbols represent data for a specific …

… with crizotinib in patients with previously untreated ALK-positive NSCLC. A clinically … seen
between the treatment arms at 5 years in favor of alectinib, although the final OS data remain …

… clinical stage, all stages have low 5-year survival … patients diagnosed with non–small cell
lung cancer (NSCLC) from 2011 to 2017, the 5-year relative survival rate was 26% in all stages …

… end points of overall survival (OS) and progression-free survival (PFS) were improved with
the programmed cell … updated survival analyses, approximately 5 years after the last patient …

… for NSCLC and an important survival landmark for patients with … in patients alive at 5
years, those who completed 2 years of … because of treatment-related adverse events (TRAEs). …

… 5-year survival in a SEER-based analysis of lung cancer, and can be explained by improvements
in treatment and/or earlier treatment … (longer recorded survival postcancer diagnosis …

… -76) years; 163 086 (52.2%) had adenocarcinoma histology. Incidence-based mortality within
5 years of … When assessing stage shift, there was significant association between year-of-…

… risk of 5-year overall survival in early-stage cancers. Procedures to … 5-year overall survival
because studies have shown that in early-stage NSCLC, 5-year and 10-year overall survival …

… the survival curve extended beyond 5 years. This suggests that long-term survival beyond 5
years may also be possible in NSCLC; … Indeed, patients with previously treated NSCLC who …

… In this study, overall incidence of recurrence during the postoperative 5 years was 20.2%
and median PRS time was 25.5 months. We examined the impact of clinicopathological …